Literature DB >> 19078712

Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP): A Review of Clinical Syndromes and Treatment Approaches in Clinical Practice.

Kenneth C Gorson1, Allan H Ropper.   

Abstract

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a chronic, acquired immune and inflammatory disorder of the peripheral nervous system. The classic form of the disorder is manifested by progressive or relapsing proximal or generalized limb weakness and areflexia, and usually easily recognized; it is the large number of regional and functional variants and variety of associated illnesses that pose a challenge to the clinician in practice. Similarly, laboratory and electromyography criteria have been developed to confirm the diagnosis; however, these various schemes are contrived because only 50% to 60% of patients with typical clinical features of CIDP fulfill these strict electrodiagnostic research criteria. Several studies have established the efficacy of immune therapies such as corticosteroids, plasma exchange, and intravenous immune globulin as the mainstay of treatment of CIDP, but these treatments might provide only short-term benefit. This review offers an approach to the evaluation and management of patients with CIDP and highlights the difficult clinical problems in those who do not respond or frequently relapse after treatment with standard therapies such as patients with CIDP and concomitant axonal loss, and the assessment of those with CIDP and concurrent diseases such as diabetes mellitus.

Entities:  

Year:  2003        PMID: 19078712     DOI: 10.1097/00131402-200306000-00004

Source DB:  PubMed          Journal:  J Clin Neuromuscul Dis        ISSN: 1522-0443


  5 in total

1.  Chronic inflammatory demyelinating polyneuropathy in a patient infected with human T lymphotropic virus type I.

Authors:  Amza Ali; Gurendra Char; Barrie Hanchard
Journal:  BMJ Case Rep       Date:  2009-08-20

2.  Standard and escalating treatment of chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Min-Suk Yoon; Andrew Chan; Ralf Gold
Journal:  Ther Adv Neurol Disord       Date:  2011-05       Impact factor: 6.570

3.  Challenges of clinical trial design when there is lack of clinical equipoise: use of a response-conditional crossover design.

Authors:  Chunqin Deng; Kim Hanna; Vera Bril; Marinos C Dalakas; Peter Donofrio; Pieter A van Doorn; Hans-Peter Hartung; Ingemar S J Merkies
Journal:  J Neurol       Date:  2011-08-07       Impact factor: 4.849

4.  The Noninvasive Diagnostic Value of MRN for CIDP: A Research from Qualitative to Quantitative.

Authors:  Yuan Feng; Xiaoyun Su; Chuansheng Zheng; Zuneng Lu
Journal:  Spine (Phila Pa 1976)       Date:  2020-11-01       Impact factor: 3.241

5.  The comparison of MRN, electrophysiology and progression among typical CIDP and atypical CIDP subtypes.

Authors:  Yuan Feng; Yu Zhang; Xiaoyun Su; Chuansheng Zheng; Zuneng Lu
Journal:  Sci Rep       Date:  2020-10-07       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.